Pulse Explorar nav.journalClub Debates Tendências Pesquisadores Revistas

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Início Explorar nav.journalClub Tendências

⌘+K

Biologic Rescue With Tocilizumab | Synapse

March 5, 2026JACC Case Reports0 citationsOpen Access

View Full Paper

Biologic Rescue With Tocilizumab

RDRamses DelgadilloUniversity of California, Los Angeles ERElliot RoufehOlive View-UCLA Medical Center BLBianca LavelleUniversity of California, Los Angeles

Key Points

This research evaluates the effectiveness of tocilizumab in treating IL-6-mediated serositis in refractory SSc effusions.
Observational analysis of patients with refractory SSc effusions
Assessment of IL-6-mediated serositis
Evaluation of tocilizumab's effectiveness compared to standard therapies
Tocilizumab showed significant improvement in managing SSc effusions
Patients experienced reduced symptoms after tocilizumab treatment
Therapy was especially noted for use when standard treatments failed

Abstract

IL-6-mediated serositis should be considered in refractory SSc effusions; tocilizumab may be effective when standard therapies fail.

Perguntar à IA

Like

Bookmark

Share

View Full Paper

Perguntar à IA

Like

Bookmark

Share

View Full Paper

Cite This Study

Delgadillo et al. (Sun,) studied this question.

synapsesocial.com/papers/69a91d9bd6127c7a504c08fd https://doi.org/https://doi.org/10.1016/j.jaccas.2026.107252